CCL21/CCR7 Promotes G2/M Phase Progression via the ERK Pathway in Human Non-Small Cell Lung Cancer Cells

Ying Xu1,2, Lifeng Liu3, Xueshan Qiu1,2, Lili Jiang1,2, Bo Huang1,2, Haiying Li1,2, Zixuan Li1,2, Wenting Luo1,2, Enhua Wang1,2

Introduction

C-C chemokine receptor 7 (CCR7) is expressed on all naive T-cells and on some memory T-cells, B-cells, and mature dendritic cells [1]. Upon interaction with its ligands, chemokine ligand 19 (CCL19) or chemokine ligand 21 (CCL21) [2], CCR7 contributes to lymphocyte trafficking and homing to lymph nodes during immune and inflammatory reactions [3–5]. CCR7 is highly expressed in non-small cell lung cancer (NSCLC), breast cancer, and squamous cell carcinoma of the head and neck and is responsible for mediating metastasis in certain cancer cells lines [6–15]. To date, the role of CCR7 in the proliferation of human NSCLC cells has not been elucidated.

Activation of CCR7 can increase phosphorylation of extracellular signal-regulated kinase (ERK) [31]. This pathway is critical for cell proliferation and survival [21,22] and is required for normal progression into mitosis [23,24]. The JNK and p38 pathways, which also include c-Jun N-terminal kinase (JNK) and p38, are activated in response to chemicals and environmental stress [25–27]. Akt (also known as Akt1), a mediator of growth factor-induced cell survival [28–30], may promote cell proliferation via phosphorylation [31].

The purpose of this study was to examine the effect and regulatory mechanism of the CCL21/CCR7 interaction on the proliferation of A549 and H460 human NSCLC cells. Here, we demonstrated that CCL21/CCR7 contributed to the time-dependent proliferation of human NSCLC cells by upregulating cyclin A, cyclin B1, and CDK1 potentially via the ERK pathway.

Results

CCL21/CCR7 promotes proliferation of A549 and H460 cells. In a previous study, we identified a higher CCR7 expression level in A549 and H460 human NSCLC cell lines compared with other cell lines [32]. To investigate the role of CCR7 in the functioning of A549 and H460 cells, CCR7 activation and inhibition were...
induced with exogenous CCL21 and with CCR7 small interfering RNA (siRNA), respectively. After transfection with CCR7 siRNA (siCCR7) or control siRNA, the expression of CCR7 was evaluated using Western blot and reverse transcriptase (RT)-PCR. We found that siCCR7 significantly downregulated the protein and mRNA levels of CCR7, compared with control siRNA (Figure 1).

To determine the effect of CCL21/CCR7 on cell proliferation, the CCK-8 assay was performed on A549 and H460 cells. According to the published data [33,34] and the results of our preliminary experiment, at 100 ng/mL concentrations CCL21 significantly promoted cell proliferation, compared with 50 ng/mL concentrations, while there were no significant difference between 100 ng/mL and 200 ng/mL concentrations (Figure 2).

Figure 1. Efficiency of CCR7 siRNA in A549 or H460 cells. A549 (A) and H460 (B) cells were transfected with control siRNA or CCR7 siRNA (siCCR7). After transfection, the expression of CCR7 protein (a) and mRNA (b) was evaluated using Western blot (a) and RT-PCR (b) and compared to untransfected A549 or H460 cells. Each bar represents the mean ± SD of three independent experiments. *p<0.05, compared with control cells. doi:10.1371/journal.pone.0021119.g001
Therefore, at 100 ng/mL concentrations CCL21 was used in the following experiment. The CCL21/CCR7 interaction significantly promoted cell proliferation, whereas siCCR7 significantly abrogated the action of CCL21 (Figure 3). siCCR7 alone had no significant effect on cell proliferation, compared with control cells. Significant differences were observed between all time point examined (all p<0.01), indicating a linear increase in proliferation with increasing exposure times to CCL21 (all p<0.01).

CCL21/CCR7 augments the proportion of cells in G2/M. To verify whether the action of CCL21/CCR7 on the proliferation of A549 and H460 cells is associated with a change in cell cycle distribution, cell cycle analysis was performed using flow cytometry. The CCL21/CCR7 interaction significantly enhanced the proportion of cells in the G2/M phase, whereas there was no significant effect of this interaction on the proportion of cells in G0/G1 or the S phase, compared with control cells (Table 1). siCCR7 significantly abolished this effect of CCL21, whereas siCCR7 alone had no significant effect on cell cycle distribution.

CCL21/CCR7 upregulates the expression of cyclin A, cyclin B1, and CDK1. To determine the possible mechanism by which CCL21/CCR7 influences the G2/M phase distribution in A549 and H460 cells, the expression of cyclins and cyclin-dependent kinase 1 (CDK1) was assessed using Western blot and real-time PCR. Compared with control cells, the CCL21/CCR7 interaction significantly upregulated the protein and mRNA levels of cyclin A, cyclin B1, and CDK1, which are related to G2/M phase progression (Figure 4). siCCR7 significantly abrogated the effects of CCL21, whereas siCCR7 alone had no significant effect on cyclin or CDK1 expression. CCL21 had no significant effect on the levels of cyclin D1 or cyclin E, which are related to G0/G1 and the G1/S transition.

CCL21/CCR7 upregulates the expression of P-ERK but not P-Akt. Others have reported that CCR7 may increase the phosphorylation of ERK, JNK, or Akt, which are related to cell survival [16–20,33,35–42]. To verify whether the CCL21/CCR7 interaction may also enhance the expression of MAPK family members and Akt in A549 and H460 cells, the expression of these components was assessed using Western blot. The CCL21/CCR7 interaction significantly upregulated the expression of P-ERK at 24 h and 48 h, whereas there was no significant impact on the expression of ERK (Figure 5). CCL21/CCR7 had no significant influence on the expression or phosphorylation of JNK, p38, or Akt. Because Akt is possibly upstream of ERK [43], A549 and H460 cells were treated with CCL21 for 24 h after a 1-h exposure to LY294002, a selective inhibitor of PI3K that inhibits activation of the downstream Akt pathway. Following this treatment, CCL21/CCR7 still significantly upregulated the expression of P-ERK (Figure 6).

Inhibition of P-ERK abolishes the impellent effects of CCL21/CCR7 on proliferation and G2/M phase progression. To verify whether PD98059, a selective inhibitor of MEK that disrupts activation of downstream ERK, can abolish the effects of CCL21/CCR7 on the proliferation and G2/M phase progression of A549 and H460 cells, cell viability and cell cycle distribution assays were performed using CCK-8 and flow cytometry, respectively. PD98059 significantly abrogated the effects of CCL21/CCR7 on cell proliferation and the G2/M phase progression (Figure 7 and Table 2, respectively). PD98059 also abolished the influence of CCL21/CCR7 on the expression of P-ERK, cyclin A, cyclin B1, and CDK1 (Figure 8). In addition, PD98059 alone had a significant inhibitory effect on the cell proliferation, the G2/M phase progression and the expression of P-ERK, cyclin A, and cyclin B1 (Figure 7, Table 2, and Figure 8, respectively).

P-ERK, induced by CCL21/CCR7, interacts with cyclin A, cyclin B1, and CDK1. To further identify whether there is an interaction between P-ERK and cyclin A, cyclin B1, or CDK1, coimmunoprecipitation was performed. A549 and H460 cells in the absence or presence of CCL21 for 24 h were subjected to immunoprecipitation with antibodies against P-ERK or IgG, followed by Western blotting for cyclin A, cyclin B1, and CDK1. A pronounced, specific interaction between P-ERK and cyclin A, cyclin B1, or CDK1 was observed, especially when the cells were treated with CCL21 for 24 h (Figure 9a). Reciprocal immunoprecipitation with antibodies against cyclin A, cyclin B1, CDK1, or IgG was assessed by Western blotting for P-ERK, and again, the interaction between P-ERK and cyclin A, cyclin B1, or CDK1 was salient, especially in the presence of CCL21 (Figure 9b). A549 and H460 cells in the absence or presence of PD98059 for 1 h were subjected to immunoprecipitation with antibodies against P-ERK or IgG, followed by Western blotting for cyclin A, cyclin B1,

Figure 2. Effect of CCL21 at various concentrations on proliferation of A549 and H460 cells. A549 (A) and H460 (B) cells were treated with CCL21 (50, 100 or 200 ng/mL) for 24, 48, or 72 h, and cell vitality was estimated using the CCK-8 assay. Each bar represents the mean ± SD of three independent experiments. **p<0.01, compared with cells treated with CCL21 (50 ng/mL). doi:10.1371/journal.pone.0021119.g002
and CDK1. The interaction between P-ERK and cyclin A, cyclin B1, or CDK1 was weakened in response to PD98059 exposure (Figure 9c).

**Discussion**

Several studies have documented that the activation of CCR7 is responsible for mediating survival of certain cancer cell lines by promoting migration and proliferation or by inhibiting apoptosis [33,35–42]. However, the role of CCR7 in the proliferation of human NSCLC cells has not been well documented. In the present study, we confirmed that the CCL21/CCR7 interaction can significantly enhance human NSCLC cell proliferation in a time-dependent manner, involving the upregulation of cyclin A, cyclin B1, and CDK1, possibly via the ERK, but not the Akt, pathway.

Consistent with previous studies using different cell models [16,37,40], the activation of CCR7 with CCL21 promoted cell proliferation. In contrast to our current findings, a prior study suggested that murine CCL21 had no significant action on the proliferation of A549 cells [44]. A possible explanation for the discrepancy would be that mouse CCL21 can interact with CXCR3 but not CCR7, whereas human CCL21 can bind CCR7 but not CXCR3 [45]. This suggests that activation of CXCR3 does not affect proliferation of A549 cells.

Traditionally, the cell cycle is segregated into four phases: DNA replication occurs during S phase, and chromosome segregation occurs during M phase. The S and M phases are separated by the so-called gap phases, G1 (before DNA replication) and G2 (before mitosis). We demonstrated that CCL21/CCR7 significantly altered cell cycle distribution such that more cells populated the G2/M phase. No significant differences were observed regarding the distribution of cells in the G0/G1 and S phases.

The cell cycle is regulated by cyclins and CDKs. D-type cyclins are regarded as key regulators of G1 progression [46]. Cyclin E is required for the G1/S transition [47,48] and cyclin A is essential for progression through the S phase [49,50]. Both cyclin A and the B-type cyclins associate with CDK1 to promote entry into mitosis [51,52]. In this study, both protein and mRNA levels of cyclin A, cyclin B1, and CDK1 were significantly upregulated when cells were treated with CCL21 for 24 h. This indicates that CCL21/CCR7 accelerates the G2/M phase progression to promote cell proliferation. No significant differences in cyclin D1 or cyclin E expression levels were measured, indicating that CCL21/CCR7 has no significant effect on the G0/G1 phase or the G1/S transition. This finding demonstrates for the first time that CCL21/CCR7 has an impellent effect on cell cycle progression involving the G2/M phase.

Consistent with previous studies using other cell types have indicated that activation of CCR7 is associated with enhanced cell survival via increased phosphorylation of ERK, JNK, or Akt [16–20,33,35–42]. We examined whether CCL21/CCR7 may enhance the expression of MAPK components and Akt in A549 and H460 cells. Our results suggested that CCL21/CCR7 enhanced the phosphorylation of ERK but not JNK, p38, or Akt. These findings are inconsistent with previously published reports that suggested a

---

**Table 1. Effect of CCL21/CCR7 on cell cycle distribution in A549 and H460 cells.**

| Group          | G2/G1 phase | S phase | G2/M phase |
|----------------|-------------|---------|------------|
|                | Mean ± SD (%) | Mean ± SD (%) | Mean ± SD (%) |
| (A549) Control | 74.35±9.67   | 23.42±12.29 | 2.23±2.82   |
| (A549) CCL21   | 66.92±1.23   | 21.60±2.91 | 11.48±2.64*|
| (A549) siCCR7/CCL21 | 69.08±10.08 | 23.90±9.28 | 6.60±2.46   |
| (A549) siCCR7 | 75.73±2.32   | 18.09±3.67 | 6.19±2.45   |
| (H460) Control | 61.50±2.70   | 31.33±3.41 | 7.17±1.63   |
| (H460) CCL21   | 60.38±6.85   | 27.08±4.13 | 12.54±2.75*|
| (H460) siCCR7/CCL21 | 69.25±4.99 | 21.40±3.23 | 6.02±2.53   |

A549 and H460 cells were treated with CCL21 (100 ng/mL) for 24 h, and cell cycle distribution was estimated using flow cytometry. Data were present as mean ± SD of three independent experiments.

*p<0.05, compared with control cells.

doi:10.1371/journal.pone.0021119.t001
The facilitative effect of CCR7 on the Akt, but not ERK, pathway [16,19]. A separate study indicated that Akt is possibly upstream of ERK [43]. We found that CCL21/CCR7 still could significantly upregulate the expression of P-ERK after the cells were treated with LY294002 for 1 h. Because LY294002 selectively inhibits PI3K to prevent downstream activation of Akt, our results strongly support the idea that CCR7 can modulate the Akt pathway.

**Figure 4.** Effect of CCL21/CCR7 on the expression of cyclins and cyclin-dependent kinases in A549 and H460 cells. A549 (A) and H460 (B) cells were treated with CCL21 (100 ng/mL) for 24 h, and the protein (a) and mRNA (b) levels of cyclins A, B1, D1, and E and of CDK1 were estimated using Western blot (a) and real-time PCR (b). Each bar represents the mean ± SD of three independent experiments. *p < 0.05 or **p < 0.01, compared with control cells.

doi:10.1371/journal.pone.0021119.g004

**Figure 5.** Effect of CCL21/CCR7 on the expression of ERK, JNK, p38, and Akt in A549 and H460 cells. A549 (A) and H460 (B) cells were treated with CCL21 (100 ng/mL) for 12, 24, or 48 h, and normal and phosphorylated (P-) expression levels were estimated by Western blot. Each bar represents the mean ± SD of three independent experiments. *p < 0.05 or **p < 0.01, compared with control cells.

doi:10.1371/journal.pone.0021119.g005
Figure 6. Effects of CCL21/CCR7 on the expression of P-ERK after inhibiting activation of Akt in A549 and H460 cells. A549 (A) and H460 (B) cells were treated with CCL21 (100 ng/mL) for 24 h after LY294002, a selective inhibitor of PI3K that consequently prevents activation of the downstream Akt, was applied for 1 h. The expression of P-ERK was estimated using Western blot. Each bar represents the mean ± SD of three independent experiments. **p<0.01, compared with control cells. doi:10.1371/journal.pone.0021119.g006

Figure 7. Effect of CCL21/CCR7 on proliferation of A549 and H460 cells after inhibiting ERK activation. A549 (A) and H460 (B) cells were treated with CCL21 (100 ng/mL) for 24, 48, or 72 h after PD98059, a selective inhibitor of MEK that disrupts activation of downstream ERK, was applied for 1 h. Cell vitality was estimated using the CCK-8 assay. Each bar represents the mean ± SD of three independent experiments. *p<0.05 or **p<0.01, compared with control cells. doi:10.1371/journal.pone.0021119.g007
suggest that Akt does not play a critical role in the interaction between CCL21/CCR7 and ERK. This is in concordance with a previous report [53]. The reason for these discrepancies remains unclear.

Since CCL21/CCR7 was capable of increasing the expression of P-ERK, we sought to determine whether there is an interaction between P-ERK and cyclin A, cyclin B1, or CDK1. Coimmunoprecipitation and reciprocal immunoprecipitation results strongly suggested an interaction between P-ERK and cyclin A, cyclin B1, or CDK1, especially in the presence of CCL21. This interaction could be weakened by inhibiting ERK with PD98059. In addition, PD98059 abolished the effect of CCL21/CCR7 on A549 and H460 cell proliferation and G2/M phase progression, as well as downregulating the expression of P-ERK, cyclin A, cyclin B1, and CDK1.

These results demonstrate that the effect of CCL21/CCR7 on cell proliferation and upregulation of cyclin A, cyclin B1, and CDK1 may occur via the ERK pathway in human NSCLC cells. This study suggests that activation of CCR7 with CCL21 can significantly promote proliferation of NSCLC cells in a time-dependent manner involving cyclin A, cyclin B1, and CDK1, possibly via the ERK, but not the Akt, pathway. This information may help clarify the mechanisms of cancer cell survival and identify potential targets for treatment of NSCLC.

Materials and Methods

Cell culture and reagents

A549 and H460 cell lines from our previous published paper [32] were cultured in RPMI-1640 or DMEM-F12 supplemented with 10% HyClone fetal bovine serum (FBS) (ThermoFisher Scientific, Fremont, CA, USA) in an atmosphere of 5% CO2 at 37°C. Cells were grown in 75 cm2 culture flasks and harvested in a solution of trypsin-EDTA at the logarithmic growth phase.

Cyclin A, cyclin B1, cyclin D1, cyclin E, CDK1, P-ERK, ERK, P38, JNK, P-p38, p38, P-Akt, Akt, IgG, and β-actin mouse or rabbit monoclonal antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Recombinant human CCL21 was purchased from Pepro Tech (Rocky Hill, NJ, USA). siCCR7 and Lipofectamine 2000 were purchased from Invitrogen (Carlsbad, CA, USA). Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Laboratories (Beijing, China). PD98059 and LY294002 were obtained from Sigma (St. Louis, MO, USA) and used at 50 μM and 100 μM (final concentrations), respectively, in accordance with previous reports [40, 54]. Protein A/G beads were obtained from Beyotime (Haimen, China).

siRNA treatment of cells

A549 and H460 cells were plated onto 6 cm2 cell culture dishes and grown to 30–50% confluence before transfection with Lipofectamine 2000 as previously described [55]. The transfection efficiency was assessed by flow cytometry. Efficiencies of siCCR7 and non-silencing control siRNA were tested using Western blot and RT-PCR. The sequences of siCCR7 and control siRNA were: CCR7, 5′-GCGUCACACCCUUCUCUGATT-3′ and 3′-UA-CAAGAAAGGGUGUGACGAG-5′; control, 5′-UUUCUGCA-ACGUCAUGUGUUCGA-5′. Cell proliferation assay

Cell proliferative activities were examined using CCK-8. A549 and H460 cells were seeded onto 96-well plates (1000 cells/well) and treated with CCK-21 for 0, 24, 48, or 72 h. After treatment, CCK-8 was added to each well according to the manufacturer’s instructions and incubated for 4 h at 37°C. The optical density (OD) value of each well was measured using a microplate reader (Spectra Thermo, Mannendorf, Switzerland) with a test wavelength of 450 nm.

Cell cycle analysis

After treatment with CCK-21 for 24 h, cells were harvested and washed twice with cold phosphate-buffered saline (PBS) and fixed in 75% ethanol for 2 h at 4°C. The fixed cells were washed twice with 500 μL of cold PBS. Cells then were stained with 500 μL of propidium iodide (PI) staining solution (50 μg/mL PI, 0.1% Triton X-100, 200 μg/mL RNase-free RNase in PBS) for 30 min at room temperature in the dark. Ten thousand events per sample were acquired using a FACS-scan flow cytometer (Becton-Dickinson, San Jose, CA, USA), and the percentage of cells in G0/G1, S, and G2/M phases of the cell cycle were determined using Modfit LT 3.0 (Becton-Dickinson).

Western blot analysis

After treatment with CCK-21 for 24 h, cells were extracted with lysis buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 2 μg/mL aprotinin and 1 mM PMSF) for 30 min at 4°C. Extracts were centrifuged at 12,000 × g for 15 min at 4°C. Supernatants containing total protein then were harvested. Aliquots, each containing 50 μg protein, were separated by 10% SDS-PAGE and transferred to PVDF membranes at 55 V (cyclin A, cyclin B1, P-Akt, Akt) or 40 V (the others) for 2.5 h at low temperature. The membranes were blocked in 5% skim milk for 2 h, and proteins were detected using monoclonal antibodies at 1:1000 (P-JNK, JNK, P-p38, p38 and β-actin) or 1:200 (the others) dilution overnight at 4°C. Proteins were visualized using anti-mouse or anti-rabbit IgG conjugated with horse radish peroxidase (HRP) at 1:6000 or 1:8000 dilution for 2 h at room temperature, respectively. Bands were imaged with an EC3 Imaging System (UVP LLC, Upland, CA, USA), and the OD was measured using ImageJ (NIH, Bethesda, MD, USA). The OD difference between tested proteins and β-actin of the same sample was calculated as relative content and expressed graphically.
RT-PCR and real-time PCR

Total RNA was isolated from cells using TRIzol (Invitrogen) according to the manufacturer’s instructions. β-Actin was used as an internal control. To determine the efficiencies of siCCR7 and control siRNA, semi-quantitative RT-PCR was performed on a G-STORM thermal cycler (GRI Ltd, Byfleet, UK) using the TaKaRa RNA PCR Kit (AMV) Ver.3.0 (TaKaRa, Dalian, China). PCR primers were as follows: CCR7 F: 5’-GAGGCTATTGTCCCCTAAACC-3’, R: 5’-TGGAGGACAGTGAAGAAAACG-3’. The CCR7 amplicon length was 305 bp. β-actin F: 5’-AAATCGTGCGTGACATTAA-3’, R: 5’-CTCGTCATACTCCTGCTTG-3’. The β-actin amplicon length was 513 bp. Other primer sequences have been published in another study [56]. The reliability of PCR results was supported by analyzing the dissociation curve. Real-time PCR data were calculated using the 2-ΔΔCT method on the SDS 2.4 software package (Applied Biosystems) [57].

Coimmunoprecipitation

After treatment with CCL21 for 24 h, cells were extracted with lysis buffer (10 mM KCl, 1.5 mM MgCl2, 10 mM HEPES [pH 7.9], 1 mM PMSF, 1 mM DTT) and homogenized for

Figure 8. Effect of CCL21/CCR7 on the expression of P-ERK, cyclin A, cyclin B1, and CDK1 after inhibiting the activation of ERK. A549 (A) and H460 (B) cells were treated with CCL21 (100 ng/mL) for 24 h after PD98059, a selective inhibitor of MEK that disrupts activation of downstream ERK, was applied for 1 h. The expression levels of these components were estimated using Western blot. Each bar represents the mean ± SD of three independent experiments. *p<0.05 or **p<0.01, compared with control cells.
doi:10.1371/journal.pone.0021119.g008
30 min at 4°C. The extracts were centrifuged at 12,000 g for 15 min at 4°C, and the supernatants containing total protein were harvested. Equal amounts of protein were exposed to antibodies against P-ERK, IgG, cyclin A, cyclin B1, or CDK1, which were immobilized on protein A/G beads. Following 3 h incubation at 4°C with gentle rotation, beads were washed extensively five times with lysis buffer, boiled, and microcentrifuged. Proteins were detected with antibodies against P-ERK, cyclin A, cyclin B1, or CDK1 by Western blot.

Statistical analysis

Data were analyzed using SPSS 16.0 software. One-way analysis of variance (ANOVA) was used to evaluate the differences between groups with various treatments, and the least significant difference (LSD) test or Dunnett T3 test was used for post hoc subgroup analysis. Polynomial contrast was used for trend analysis. All data are presented as the mean ± SD of three independent experiments. Results were considered statistically significant for p < 0.05. N-fold values for gene expression change up to 0.5 and below 2 were taken as nonsignificant in accordance with values obtained from negative control genes [57,58].

Author Contributions

Conceived and designed the experiments: YX XQ. Performed the experiments: YX LL LJ BH HL ZL WL EW. Analyzed the data: YX LL. Contributed reagents/materials/analysis tools: XQ. Wrote the paper: YX.

References

1. Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392: 565–8.
2. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12: 121–7.
3. Dieu MC, Vanhverdt B, Vicari A, Bridon JM, Oldham E, et al. (1998) Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188: 573–86.
4. Hiroa M, Onai N, Hiroihi K, Watkins SC, Matsumi A, et al. (2000) CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 60: 2209–17.
5. Sozzani S, Allavena P, D’Amico G, Laini W, Bianchi G, et al. (1998) Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol 161: 1003–6.
6. Muller A, Homay B, Soto N, Ge N, Catron D, et al. (2003) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50–6.
7. Takagaki T, Fujimoto T, Tanaka M, Yamamoto T, Houch E, et al. (2004) CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 10: 2351–8.
8. Mori T, Imai J, Yamano T, Takeuchi H, Huang S, et al. (2005) Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 65: 1800–7.
9. Ishigami S, Natsugoe S, Nakajo A, Tokuda K, Uno S, et al. (2007) Prognostic value of CCR7 expression in gastric cancer. Hepatogastroenterology 54: 1025–8.
10. Kodama J, Hasanawawa, Kusumoto T, Seki N, Matsuo T, et al. (2007) Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol 18: 70–6.
11. Wiley HE, Gonzalez EB, Maki W, Wuyang ST, (2001) Expression of CC chemokine receptor 7 and regional lymph node metastasis in human cervical cancer. J Natl Cancer Inst 93: 1638–43.
12. Wang J, Zhang X, Thomas SN, Grandis JR, Wells A, et al. (2005) Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and pro-survival
pathways in head and neck cancer cells independent of EGFR. Oncogene 24: 5897–904.

17. Li Z, Li J, Mo B, Hu C, Liu H, et al. (2008) Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Carcinogenesis 29: 1511–16.

18. Wu Y, Peng H, Cui M, Whitney NP, Huang Y, et al. (2009) CXCL12 increases human neural progenitor cell proliferation through Akt-1/FOXO3a signaling pathway. J Neurochem 109: 1157–67.

19. Sánchez-Sánchez N, Riol-Blanco L, de la Rosa G, Puig-Kröger A, García-Bordás J, et al. (2004) Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 104: 619–23.

20. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, et al. (2004) The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 39: 1642–50.

21. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37–47.

22. Li Y, Lapraptz, R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911–2.

23. Wright JH, Muenar E, Jameson DR, Andreassen PR, Margolis RL, et al. (1999) Mitogen-activated protein kinase cascade activity is required for the G2/M transition of the cell cycle in mammalian fibroblasts. Proc Natl Acad Sci U S A 96: 11335–40.

24. Hayne C, Trizion G, Lao Z (2000) Raf1/MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole. J Biol Chem 275: 31876–82.

25. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 101: 251–61.

26. Minden A, Karin M (1997) Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1333: F85–104.

27. Roullard A, Reinhardt C, Anini P, Williams LT (1998) Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 273: 10232–9.

28. Kulik G, Klippel A, Weber MJ (1997) Antiapoptotic signalling by the insulin-like N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 273: 10232–9.

29. Banas B, Wo¨rnle M, Merkle M, Gonzalez-Rubio M, Schmid H, et al. (2004) Effects of chemokines on human 6C-kine induction and protection of circulating CD8+ primary T lymphocytes. J Biol Chem 283: 38781–7.

30. Iijima N, Yanagawa Y, Clingan JM, Onoe K (2003) CCR7-mediated c-Jun N-terminal kinase activation regulates cell migration in mature dendritic cells. Int Immunol 17: 1201–12.

31. Liu FY, Zhao ZJ, Li P, Ding X, Zong ZH, et al. (2010) Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous carcinoma of the head and neck. Br J Oral Maxillofac Surg 48: 291–6.

32. Baer G, Borhis G, Treton D, Richard Y (2005) IFN[alpha] enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization. Int Immunol 17: 459–67.

33. Carrozza AP, Agnon MK, Ward SG (2002) Chemokine signalling: pivoting around multiple phosphoinositol 3-kinases. Immunology 103: 125–36.

34. Arenberg DA, Zlotnick A, Strom SR, Burdick MD, Streiter RM (2003) The murine CCR chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol Immunother 52: 587–92.

35. Jesch GH, Cox MA, Kaminski H, Zhang M, Byrnes H, et al. (1999) Cutting edge: species specificity of the CCR chemokine 6C-kine signaling through the CXC chemokine receptor CCR3: human 6C-kine is not a ligand for the human or mouse CCR3 receptors. J Immunol 162: 3765–9.

36. Nigg EA (1995) Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 17: 471–80.

37. Knöblach JA, Sauer K, Jones I, Richardson H, Saint R, et al. (1994) Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell 77: 167–20.

38. Ohtsubo M, Roberts JM (1993) Cyclin-dependent regulation of G1. Mol Cell Biol 13: 5606–11.

39. Kauffmann-Zeh A, Rodriguez-Viciana P, Urich E, Gilbert C, Coffler P, et al. (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI3K and PKR. Nature 385: 544–8.

40. Dedk H, Datta SR, Franke TF, Bierbaum MJ, Yao R, et al. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 276: 651–5.

41. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Joo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 95: 857–68.

42. Li Y, Qiu X, Zhang S, Zhang Q, Wang E (2009) Hypoxia induced CCR7 expression via HIF-1α and HIF-2α correlates with migration and invasion in lung cancer cells. Cancer Biol Ther 8: 322–30.

43. Banas B, Wörnle M, Merkle M, Gonzalez-Rubio M, Schmid H, et al. (2004) Binding of the chemokine SLC/CCL21 to its receptor CCR7 increases adhesive properties of human mesangial cells. Kidney Int 66: 2256–63.

44. Wörnle M, Schmid H, Merkle M, Banas B (2008) Effects of chemokines on proliferation and apoptosis of human mesangial cells. BMC Nephrol 9: 8.

45. Kim JW, Ferris RL, Whiteside TL (2005) CCR7/CCL21 promotes G2/M Phase Progression of the cell cycle in mammalian fibroblasts. Science 259: 1908–12.

46. Girard F, Straussfeld U, Fernandez A, Lamb NJ (1991) CCR7 is a receptor for the CCR chemokine 6C-kine and inhibits tumor growth and angiogenesis in a human lung tumor xenograft. Cancer Immunol Immunother 249: 587–92.

47. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37–47.

48. Ohtsubo M, Roberts JM (1993) Cyclin-dependent regulation of G1. Mol Cell Biol 13: 5606–11.

49. Knöblach JA, Sauer K, Jones I, Richardson H, Saint R, et al. (1994) Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell 77: 167–20.

50. Ohtsubo M, Roberts JM (1993) Cyclin-dependent regulation of G1. Mol Cell Biol 13: 5606–11.

51. King RW, Jackson PK, Kirschner MW (1994) Mitosis in transition. Cell 79: 365–71.

52. Knöblach JA, Lehnert CF (1993) Synergistic action of Drosophila cyclins A and B during the G2-M transition. EMBO J 12: 65–74.

53. Riol-Blanco L, Sánchez-Sánchez N, Torres A, Tejedor A, Narumiya S, et al. (2005) The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J Immunol 174: 4070–80.

54. Weigel B, Bjaellt A, Cukiz Z, Persson JL (2008) Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 122: 1521–9.

55. Rudl BD, Burstein E, Buckett CS, Li X, Lukacs NW (2005) Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 79: 3350–7.

56. Liu L, Zhu Y, Xu Y, Reiter RJ (2011) Melatonin delays cell proliferation by inducing G1 and G2/M phase arrest in a human osteoblastic cell line hFOB 1.19. J Pineal Res 50: 222–31.

57. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta Delta C(T)] Method. Methods 25: 402–8.

58. Pizarro JG, Yeste-Velasco M, Esparza JL, Verdaguer E, Pallàs M, et al. (2008) The antiproliferative effect of melatonin in B6C rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycle-related genes. J Pineal Res 45: 8–16.